Dimethyl fumarate Teva Liên Minh Châu Âu - Tiếng Iceland - EMA (European Medicines Agency)

dimethyl fumarate teva

teva gmbh - dímetýl fúmarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - Ónæmisbælandi lyf - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Dimethyl fumarate Accord Liên Minh Châu Âu - Tiếng Iceland - EMA (European Medicines Agency)

dimethyl fumarate accord

accord healthcare s.l.u. - dímetýl fúmarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - Ónæmisbælandi lyf - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Sendoxan Stungulyfsstofn, lausn 1 g Iceland - Tiếng Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

sendoxan stungulyfsstofn, lausn 1 g

baxter medical ab* - cyclophosphamidum inn - stungulyfsstofn, lausn - 1 g

Sendoxan Stungulyfsstofn, lausn 500 mg Iceland - Tiếng Iceland - LYFJASTOFNUN (Icelandic Medicines Agency)

sendoxan stungulyfsstofn, lausn 500 mg

baxter medical ab* - cyclophosphamidum inn - stungulyfsstofn, lausn - 500 mg

Aubagio Liên Minh Châu Âu - Tiếng Iceland - EMA (European Medicines Agency)

aubagio

sanofi winthrop industrie - teriflunomide - margvísleg sclerosis - valdar ónæmisbælandi lyf - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Teriflunomide Mylan Liên Minh Châu Âu - Tiếng Iceland - EMA (European Medicines Agency)

teriflunomide mylan

mylan pharmaceuticals limited - teriflunomide - heila-og mænusigg, köstum tilkynnt - Ónæmisbælandi lyf - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).